生命科学资讯

#ASH25: New data from Gilead, J&J set up a bispecific, CAR-T rivalry

Does Surging Genomics Consumables Demand Reshape The Bull Case For Illumina’s Recurring Revenue Engine (ILMN)? - Yahoo Finance

Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Mar - pharmiweb.com

J&J-backed Cellular Origins raises $40M for cell therapy manufacturing

Novartis notches another win for drug acquired in MorphoSys deal

Pfizer adds heft to obesity pipeline in $2B Yaopharma deal

Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific

Aimedbio debuts with $48M Kosdaq IPO

Kazia raises AU$50M to advance PI3K/mTOR inhibitor paxalisib

14 psoriasis therapies projected to launch in China by 2027

SanegeneBio raises $110M in follow-up to metabolic deal with Lilly

Novartis to partner with AI-focused Relation on atopic diseases

Structural basis of microtubule-mediated signal transduction

Biomaterial-minimalistic photoactivated bioprinting of cell-dense tissues

ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma

ASH: Novartis details ianalumab's phase 3 win in rare blood disease

Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug

Ose narrows focus to conserve cash at expense of wider pipeline

ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma

Pfizer dips into China for another try at an obesity pill